Tuberculosis (TB) remains a major global health problem, particularly in many of the developing countries including India. Some of the factors that have substantially contributed to the number of multi-drug resistant tuberculosis (MDRTB) and extensively drug resistant tuberculosis (XDRTB) cases both in general and among HIV infected persons arethe delay in the diagnosis as well as delayed deter...

We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-resistant tuberculosis when treatment options are limited.

In Ulaanbaatar, Mongolia, multidrug-resistant tuberculosis (MDR TB) was diagnosed for more than a third of new sputum smear-positive tuberculosis patients for whom treatment had failed. This finding suggests a significant risk for community-acquired MDR TB and a need to make rapid molecular drug susceptibility testing available to more people.

tuberculosis is one of the most important infectious diseases and a major cause of morbidity and mortality in developing countries. multi drug resistant tuberculosis is a new threat, which can result in a high case fatality rate. this study was conducted to define the incidence of multidrug resistant tuberculosis in kermanshah. ­antibiogram was performed on­­ pcr-confirmed isolates of mycobacte...

Multidrug-resistant Gram-negative bacteria are a major public health threat. However, intense efforts to limit their spread, the number of multidrug resistant Gram-negative bacteria continues to increase globally. Carbapenems, the most broad-spectrum beta lactam antibiotics active against Gram-negative organisms, are very slowly hydrolyzed by most beta-lactamases. Because of their broad-spectru...

Fluoroquinolones are a key component of multidrug-resistant tuberculosis treatment. We describe the first reported case of probable levofloxacin-associated intracranial hypertension in a 6-year-old girl with pulmonary multidrug-resistant tuberculosis. The case highlights the potential risk of secondary intracranial hypertension in multidrug-resistant tuberculosis patients who require prolonged ...

Increasing resistance among Gram-negative uropathogens limits treatment options, and susceptibility data for multidrug-resistant isolates are limited. We assessed the activity of five oral agents against 91 multidrug-resistant Gram-negative urine isolates that were collected from emergency department/hospitalized patients. Fosfomycin and nitrofurantoin were most active (>75% susceptibility). Su...

BACKGROUND Multidrug-resistant tuberculosis has emerged as a global threat. The aim of this work was to compare the CT findings of primary multidrug-resistant tuberculosis and drug-sensitive tuberculosis in non-AIDS adults. MATERIAL AND METHODS From January 2012 to February 2016, 89 patients with primary multidrug-resistant tuberculosis were retrospectively reviewed, and 89 consecutive drug s...

Tuberculosis, in particular drug-resistant tuberculosis, is of global concern due to the high mortality and morbidity associated with it annually. The aim of this study was to determine the prevalence of and the risk factors for multidrug-resistant tuberculosis in Iran and its neighboring countries. Four databases (PubMed, BioMed Central, EMBASE, and Web of Science) were searched using key term...

BACKGROUND Multidrug-resistant tuberculosis (MDR-TB) is an important global health problem, and a control strategy known as DOTS-Plus has existed since 1999. However, evidence regarding the feasibility, effectiveness, cost, and cost-effectiveness of DOTS-Plus is still limited. METHODOLOGY/PRINCIPAL FINDINGS We evaluated the feasibility, effectiveness, cost, and cost-effectiveness of a DOTS-Pl...